Melanoma - Systemic Therapies and Clinical Evidence

Chemotherapy, Targeted Therapy, and Immunotherapy for Metastatic Melanoma Introduction Metastatic melanoma is a serious form of skin cancer that has spread beyond its original location. Over the past few decades, treatment approaches have evolved dramatically—from traditional chemotherapy that showed limited benefit, to targeted therapies that attack specific mutations in melanoma cells, to immunotherapies that harness the patient's own immune system. This guide covers three main treatment strategies: chemotherapy, targeted therapy, and immunotherapy, and explains how and when each is used. Chemotherapy: Historical Context and Current Role Dacarbazine and Its Limitations Dacarbazine has been used to treat metastatic melanoma since the 1970s. While it can shrink tumors in some patients, a critical limitation is that randomized controlled trials have failed to demonstrate that dacarbazine actually improves overall survival—meaning patients do not live longer, even if their tumors temporarily shrink. Temozolomide as an Oral Alternative Temozolomide is an oral chemotherapy drug that works similarly to dacarbazine. Because it can be taken by mouth rather than given intravenously, it offers convenience. However, temozolomide is generally considered a possible later-line option, typically used only after immune checkpoint inhibitors have been tried. Like dacarbazine, it can produce tumor responses but does not consistently improve overall survival. Other Chemotherapy Agents Additional alkylating agents (a class of chemotherapy drugs) such as fotemustine exist, and sometimes drug combinations are used. While these agents can shrink tumors, they similarly fail to consistently improve overall survival, which is why chemotherapy alone is no longer considered first-line treatment for metastatic melanoma. Targeted Therapy: Precision Treatment Based on Tumor Mutations Why Targeted Therapy Works: The Molecular Basis Many melanoma cells carry specific mutations—permanent changes in their DNA—that drive uncontrolled cell growth. The most common of these is the BRAF V600E mutation, found in roughly half of melanomas. By understanding these mutations, scientists developed small-molecule inhibitors: drugs designed to fit into and block the mutant proteins that cancer cells depend on. This approach is far more effective than traditional chemotherapy because it specifically targets cancer cells while minimizing damage to healthy cells. BRAF Inhibitors: The First Line of Targeted Therapy Vemurafenib and dabrafenib are selective inhibitors of mutant BRAF V600E protein. These drugs can produce rapid tumor responses in patients whose melanomas carry this mutation. However, a critical limitation emerged: while BRAF inhibitors work quickly, melanoma cells often develop resistance within months. When the cancer becomes resistant to a BRAF inhibitor alone, the tumor begins growing again. Combining BRAF and MEK Inhibition for Better Outcomes The solution to resistance proved to be combination therapy. Trametinib is a MEK inhibitor—it blocks a protein called MEK that acts downstream of BRAF in the same cancer-driving pathway. When trametinib is combined with a BRAF inhibitor (such as dabrafenib), the results are substantially better: Faster tumor shrinkage: Combined therapy produces faster initial responses compared to BRAF inhibition alone More durable responses: Tumors remain controlled longer before resistance develops Delayed resistance: The combination slows the emergence of treatment-resistant cancer cells This happens because blocking both BRAF and MEK simultaneously hits the cancer pathway with a one-two punch, making it harder for the cancer to escape. Clinical Outcomes with Combined Targeted Therapy The dabrafenib-trametinib combination has set the benchmark for targeted therapy outcomes: Three-year progression-free survival: Approximately 23% (meaning about 23% of patients remain cancer-free for at least 3 years) Five-year progression-free survival: Approximately 13% For patients whose tumors lack the BRAF mutation, encorafenib (another BRAF inhibitor) combined with binimetinib (another MEK inhibitor) is available as an alternative combination with similar logic and benefit. Immunotherapy: Unleashing the Immune System How Immunotherapy Works Rather than directly poisoning cancer cells (as chemotherapy does) or blocking a specific cancer-driving mutation (as targeted therapy does), immunotherapy takes a different approach: it stimulates the patient's own immune system to recognize and destroy melanoma cells. This is elegant because the immune system can adapt and evolve, potentially providing more durable control of the cancer. Cytokine Therapies: The Early Immunotherapy Approach Interferon-alpha and interleukin-2 (IL-2) are cytokines—signaling molecules that activate immune cells. These were among the earliest immunotherapy approaches for melanoma. Interleukin-2 is particularly notable: while it produces serious side effects (high fevers, low blood pressure, organ toxicity), in a small subset of patients it can achieve complete, long-lasting remission of their cancer. This demonstrates the potential power of immunotherapy, even though most patients don't benefit. Immune Checkpoint Inhibitors: The Modern Immunotherapy Revolution The breakthrough in melanoma immunotherapy came with understanding immune checkpoints—natural "brakes" that prevent the immune system from attacking the body's own cells. Melanoma cells exploit these brakes to hide from immune attack. Two classes of checkpoint inhibitors have transformed melanoma treatment: Anti-CTLA-4 Antibodies (Ipilimumab and Tremelimumab) CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a "brake" on T cells. Ipilimumab is a monoclonal antibody that blocks CTLA-4, allowing T cells to become more active and attack melanoma. In a phase III clinical trial, ipilimumab improved overall survival in patients with previously untreated metastatic melanoma—a major milestone. Importantly, adding dacarbazine chemotherapy to ipilimumab did not further increase survival, confirming that ipilimumab's benefit is independent and sufficient. Anti-PD-1 Antibodies (Pembrolizumab and Nivolumab) PD-1 (programmed death-1) is another immune checkpoint that melanoma cells use to suppress immune attack. Pembrolizumab and nivolumab are monoclonal antibodies that block PD-1 and enhance T-cell activity against melanoma. Compared to anti-CTLA-4 antibodies: Anti-PD-1 antibodies provide greater efficacy—they produce better tumor responses in more patients Anti-PD-1 antibodies cause less systemic toxicity—they have fewer severe side effects Pembrolizumab has achieved a five-year progression-free survival rate of approximately 21%, which is comparable to or better than targeted therapy for BRAF-mutant melanoma, and it works regardless of BRAF mutation status. Adjuvant Immunotherapy: Preventing Recurrence After surgical removal of stage IIB-C melanoma (intermediate-stage disease), observation is traditionally an option. However, nivolumab or pembrolizumab given as adjuvant therapy (treatment after surgery to prevent recurrence) significantly improves recurrence-free survival—meaning patients stay cancer-free longer after their tumor is surgically removed. Combining Checkpoint Inhibitors for Advanced Disease In patients with unresectable stage III or IV melanoma (cancer that cannot be surgically removed), dual checkpoint blockade with nivolumab plus ipilimumab followed by maintenance nivolumab produces superior results compared to either drug alone. This combination increases overall survival, though at the cost of increased immune-related adverse reactions—unwanted effects from heightened immune activation, such as colitis, hepatitis, or pneumonitis. Advanced Approaches and Special Therapies <extrainfo> Oncolytic Viral Therapy: T-VEC Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex virus designed to replicate specifically in tumor cells while producing granulocyte-macrophage colony-stimulating factor (GM-CSF), a powerful immune-stimulating molecule. A randomized clinical trial demonstrated that T-VEC improves the durable response rate in patients with advanced melanoma, representing a novel mechanism of immunotherapy distinct from checkpoint inhibition. </extrainfo> Key Takeaways for Clinical Practice Understanding these three treatment modalities and their appropriate use is essential: Chemotherapy (Dacarbazine, Temozolomide): Limited role due to lack of survival benefit; now used only as later-line options after other therapies have been attempted. Targeted Therapy (BRAF/MEK Inhibitors): Highly effective for the 50% of melanomas with BRAF mutations; produces rapid responses but can lead to resistance; combination BRAF-MEK therapy delays resistance and improves durability compared to BRAF inhibition alone. Immunotherapy (Checkpoint Inhibitors): Effective regardless of mutation status; anti-PD-1 antibodies (pembrolizumab, nivolumab) are preferred over anti-CTLA-4 due to better efficacy and tolerability; can be used alone or in combination; capable of producing durable responses and is appropriate for adjuvant (post-surgical) treatment. The choice between targeted therapy and immunotherapy depends on BRAF mutation status, stage of disease, and individual patient factors. Modern melanoma treatment often involves sequential or combined use of these approaches based on the tumor's characteristics and how it responds to therapy.